The Infusion Providers Alliance submitted to the House Energy & Commerce Health Subcommittee the attached testimony for an April 26 hearing titled “Lowering Unaffordable Drug Costs: Legislative Solutions to Increase Transparency and Competition in Health Care.” A subcommittee summary of the legislation to be discussed can be found here. Our testimony specifically addresses:
- A modified approach to site neutrality legislation that aligns payment rates across sites of care based on volume;
- Support for a Part B co-payment cap rate for physician offices and freestanding infusion centers; and
- Support for oversight of the pharmacy benefit management industry.